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Objective. As anti-amyloid therapeutic interventions shift from enrolling patients with Alzheimer’s 
disease (AD) dementia to individuals with pre-clinical disease, the need for sensitive measures that 
allow for non-invasive, fast, disseminable and cost-effective identification of preclinical status 
increases in importance. The recency ratio (Rr) is a memory measure that relies on analysis of serial 
position performance, which has been found to predict cognitive decline and conversion to early mild 
cognitive impairment (MCI). The aim of this study was to test Rr’s sensitivity to cerebrospinal fluid 
(CSF) levels of the core AD biomarkers in individuals with MCI-AD and controls.  
Methods. Baseline data from 126 (110 controls and 16 MCI-AD) participants from the Wisconsin 
Alzheimer’s Disease Research Center were analysed. Partial correlations adjusting for demographics 
were carried out between CSF measure of amyloid beta (Aβ40, Aβ42 and the 40/42 ratio) and tau 
(total and phosphorylated), and memory measures (Rr, delayed recall and total recall) derived from 
the Rey’s Auditory Verbal Learning Test.  
Results. Results indicated that Rr was the most sensitive memory score to Aβ42 levels in MCI-AD, 
while no memory score correlated significantly with any biomarker in controls.  
Conclusions. This study shows that Rr is a sensitive cognitive index of underlying Amyloid β 
pathology in MCI-AD.   
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Key points: This paper confirms that the recency ratio is a valuable cognitive index, and shows its 










The recency ratio (Rr) [1-3] is a novel measure of memory performance that aims to identify 
individuals at risk of Alzheimer’s disease (AD) and neurodegeneration. Sensitivity of Rr is based on 
the observations that individuals with AD, compared to controls, when asked to learn and recall 
information, present a typical pattern whereby: a) immediate recall of the most recently presented 
information (i.e., recency words – last few learned) is higher relative to earlier presented information, 
and to controls; whereas b) the delayed recall of recency words is usually very poor [4]. Therefore, we 
postulated that the ratio between immediate and delayed recency would be higher in individuals with 
more AD pathology. Consistent with this assertion, we have shown that higher (i.e., worse) Rr scores 
predict subsequent cognitive decline [1], and are linked with greater risk of preclinical (early) mild 
cognitive impairment (MCI) [3]. Moreover, initial, unpublished evidence suggests Rr scores are 
substantially higher in AD than in other types of dementia, such as dementia with Lewy bodies [5]. 
However, the relationship between Rr and AD biomarkers is yet to be examined. 
In the current study, we set out to test the hypothesis that Rr is sensitive to conventional 
biomarkers of AD by assessing the relationship between Rr and CSF levels of Amyloid Beta 1-42 
(Aβ42), total tau (T-tau), and phosphorylated tau (P-tau), in addition to Amyloid Beta 1-40 (Aβ40), 
and the Aβ40/Aβ42 ratio. The first three biomarkers provide the basis for the objective, biomarker-
based (A/T/N; 6) classification of AD cases. Disturbances in Aβ42 dynamics emerge early in the 
pathophysiology of AD and decades before the appearance of pathological cognitive decline [7]. 
Aβ42 plays a central role in the formation of senile plaques resulting from the peptide’s misfolding to 
form oligomers and fibrils. In contrast, alterations in T-tau and P-tau have been reported to be more 
proximal to clinical symptoms, and generally thought to reflect later neuropathology associated with 
AD [8], including increases in neurofibrillary tangles formation, and synaptic and neuronal 
degeneration. Unlike with tau, CSF Aβ42 levels are reduced when the amyloid burden is higher in the 
brain [9], probably due to reduced clearance. Therefore, we would expect a cognitive marker sensitive 
to early AD pathology would be associated with lower CSF Aβ42 levels, indicating increased amyloid 
load in the brain. In contrast, a cognitive marker sensitive to progressed disease burden would 
measure neuronal dysfunction and tau dysmetabolism that may relate to neurodegeneration and tangle 




formation, i.e., CSF T-tau and P-tau levels. We also examined whether Rr showed a stronger 
relationship with CSF markers than either traditional AVLT summary score (total recall across 
learning trials and delayed recall).  
To test whether Rr was sensitive to AD biomarkers, we carried out cross-sectional analyses 
using data obtained from the University of Wisconsin – Madison’s Wisconsin Alzheimer’s Disease 
Research Center (ADRC). As individuals with MCI-AD and cognitively healthy controls are distinct 
clinical entities, we conducted separate analyses within each group. Individuals with MCI-AD are at 
greater risk of AD than controls, but conversion to dementia is not inevitable. Discerning those likely 
to convert from those whose impairment is stable would allow for targeted and cost-effective 
interventions. Presently, methods to assess likelihood of conversion are invasive and resource intense, 
e.g., CSF collection from lumbar puncture or PET imaging of amyloid and tau. It is critical, therefore, 
to develop measures that allow a non-invasive, disseminable, and cost-effective identification of who 
is most likely to progress to the dementia stage of AD, especially in at-risk cohorts. 
Methods 
Participants. Participants were recruited from Wisconsin ADRC. All participants provided informed 
consent for participation and use of their data for research. The study was approved by the University 
of Wisconsin – Madison IRB, and by Liverpool John Moores University Ethics panel. Data were 
analysed cross-sectionally (baseline) from 126 participants fulfilling the following criteria: a) 
diagnosis of MCI-AD or classification as cognitively normal; b) complete Rey Auditory Verbal 
Learning Test data; and c) available CSF Aβ40, Aβ42, T-tau and P-tau levels collected within 12 
months of cognitive data. The cognitive status (MCI-AD, cognitively healthy) was determined via a 
consensus conference, during which cognitive data, Clinical Dementia Rating collateral reports, and 
medical history were reviewed by a team of neuropsychologists, neurologists, geriatricians and nurse 
practitioners. MCI-AD here refers to participant characteristics consistent with National Institute on 
Aging-Alzheimer's Association (NIA-AA) criteria of early cognitive deficits on path to AD, without 
reaching the threshold for a full diagnosis of dementia [10]. Overall, 110 individuals were controls, 
and 16 participants had MCI-AD.  




Aβ and Tau. CSF Aβ40 and Aβ42 levels were measured using the MSD Abeta Triplex assay (Meso 
Scale Discovery, Rockville, MD), as described by the manufacturer. Tau levels were analyzed using 
commercially available enzyme-linked immunosorbent assay (ELISA) methods (INNOTEST assays, 
Fujirebio, Ghent, Belgium). All analyses were performed by board-certified laboratory technicians 
blinded to clinical information. 
Procedure. Lumbar punctures for CSF collection were performed by trained clinicians using Sprotte 
25-gauge spinal needles, inserted between L4 and L5, after administration of 1% lidocaine s.c.. 
Polypropylene tubes were used for both collection and storage. Approximately 22ml of CSF were 
collected, immediately processed, divided into 0.5 ml aliquots and stored at -80°C for future assays. 
Samples were then shipped to the University of Gothenburg, Sweden, for determination. Average 
time between CSF collection and neuropsychological assessment was 0.19 years (SD=0.18) for 
controls, and 0.20 years (SD=0.13) for individuals with MCI-AD. 
The Rey’s Auditory Verbal Learning Test (AVLT) was used to assess learning and memory 
performance. In the AVLT, a list of 15 semantically unrelated words is presented verbally to the 
participants once, after which they are asked to free recall as many words as possible. Subsequently, 
this presentation-test routine (learning trials) is repeated four more times. A total recall score is 
determined by adding the number of recalled items for the five learning trials. After presentation of a 
distractor list and a delay of approximately 20 minutes, participants are asked to freely recall items 
from the original word list. A delayed recall score is then derived from this test. The verbatim recall 
was recorded for all learning and delayed recall trials. 
Recency ratio. Recency was defined as the last four items presented in the AVLT word list. Rr was 
calculated by dividing the recency scores in the first recall test (trial 1 of the AVLT), by the 
corresponding scores in the very last recall test (delayed trial). An Rr score was calculated for each 
participant. As customary [3], a correction was applied ((immediate recency score + 1) / (delayed 
recency score + 1)) to avoid missing data due to zero scores. 
Design and Analysis. Partial Bivariate Pearson’s correlations, controlling for age, years of education 
and gender, were carried out separately for the controls and individuals with MCI-AD. Correlated 
variables were (natural log) transformed Rr, the AVLT total recall score, the AVLT delayed recall 




score, and (natural log) transformed Aβ40, Aβ42, the 40/42 ratio, T- and P-tau, all of which 
distributed normally or close to it. Bootstrapping (1000 samples) was also performed, and false 
discovery rate (FDR; 11) p-values were calculated for each set of analyses (controls and MCI-AD) 
separately to control for multiple tests. 
Results 
Table 1 reports demographics data for the study participants. Participants with MCI-AD were 
generally older and performed more poorly at memory tests. CSF Aβ42 levels and ratio scores were 
lower and higher, respectively, in individuals with MCI-AD, suggesting increased brain amyloid load. 
However, although T-tau was higher in individuals with MCI-AD, P-tau was not, despite high 
correlations between T- and P-tau in both participants groups (R≥0.890). 
MCI-AD group. As anticipated, Rr was negatively correlated with CSF Aβ42 in individuals with 
MCI after partialling out age, education and sex, (R=-0.762, p=0.002; bootstrapped 95% confidence 
interval -0.952 to -0.198). This result suggests that higher Rr scores were associated with increased 
brain amyloid load. In contrast, neither total (p=0.357) nor delayed recall (p=0.107) were significantly 
correlated with CSF Aβ42 levels. None of the three memory scores appeared to be sensitive to CSF 
Aβ40 levels (p > 0.490 for all three tests), or T- and P-tau levels (p > .15 for all six tests). Rr was 
significantly correlated with the 40/42 ratio score (R=0.624, p=0.023), but bootstrapped 95% 
confidence interval were not of the same sign: -0.021 to 0.906. See Table 2 for partial correlation 
coefficients, p-values, FDR-adjusted p-values, and bootstrapped 95% confidence intervals.  
Cognitively intact group. In cognitively unimpaired controls, correlation coefficients were much 
smaller than in the MCI-AD group, and none of the relationships between memory and CSF measures 
were significant after adjusting for age, education and sex (p>16; see Table 2). 
Rr and adjusted CSF Aβ42 in both groups. Figure depicts the correlations between CSF Aβ42 
(adjusted for age, education and sex) and log-transformed Rr in MCI-AD and controls. Notably, MCI-
AD subjects tend to cluster around higher Rr scores and lower CSF Aβ42 levels, respectively, 
consistent with the differences reported in Table. We also report the same plot with T-tau for 
comparison. 
 





The results of the cross-sectional analysis on baseline data, collected from participants enrolled 
in the Wisconsin ADRC Clinical Core, show that Rr is a sensitive measure of CSF Aβ42 levels in 
individuals with MCI-AD, performing significantly better than standard neuropsychological measures 
of memory, such as AVLT total and delayed recall. In contrast, no memory score was sensitive to 
CSF Aβ42 levels in controls, nor any score correlated significantly with Aβ40, the 40/42 ratio, T- or 
P-Tau levels in either cohort. 
The basis for the association between Rr and CSF Aβ42 is not known. Increased amyloid 
burden in AD tends to develop first in default mode network (DMN) areas, leading to reduced 
connectivity within these areas, and between the DMN and the frontoparietal network [12]. In 
contrast, early tau pathology has been detected primarily in the medial temporal lobe [13]. Therefore, 
it is possible that Rr may be sensitive to the adverse effects of early brain amyloid deposition, and 
specifically as it affects connectivity in and around the DMN. It is also to note that increases in 
Amyloid β oligomers and deposition in the neocortex have been associated with a disruption of the 
glutamatergic-gabaergic balance, and widespread abnormal increases in neuronal activity, which can 
extend to the hippocampus [14-16]. Hippocampal neuronal hyperactivity has been reported in MCI, 
and is implicated in cognitive dysfunction [17; see also 18 for a wider discussion on hyperactivity]. 
Therefore, future studies with appropriate neuroimaging techniques including PET indices of 
Amyloid burden and fMRI should be conducted to determine the role, if any, that these factors may 
have in the modulation of Rr. 
A clear limitation of this study is the low sample size in the MCI-AD group, which totalled at 
16 individuals. Additionally, brain AD biomarkers were not examined. Nonetheless, further research 
is needed to confirm these findings. Another possible limitation is that the time interval between CSF 
and cognitive measurements was roughly two months. While cognitive ability is not expected to 
change significantly during such a short time period, as cognitive change, even in MCI-AD, is 
expected to be rather slow, CSF biomarkers may turn over faster than two months. However, there is 
typically more concern about diurnal shifts in CSF proteins than month to month changes (19), and it 




is generally accepted that changes in CSF biomarkers levels reflecting brain changes will also 
progress slowly. Therefore, two months should represent a broadly acceptable interval length.   
Rr represents a non-invasive, cost-effective, rapid and accessible test, which can be easily 
calculated from common neuropsychological test batteries of recall performance, including the 
AVLT, as long as learning items are not semantically related. Due to its sensitivity to CSF Aβ42 
levels in MCI-AD, as well as its usefulness to predict pre-clinical MCI (3) and CSF glutamatergic 
abnormalities (2), we recommend that it is considered as part of screening batteries for early-stage 
therapeutic trials in AD. Moreover, as we have argued in the past, we recommend that serial position 
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Table 1. Demographics. N = number of participants included in the analysis who were either 
cognitively normal or had a diagnosis of MCI-AD; Age in years (mean, standard deviation, and 
range); Gender (number of females and percentage); Education in years (mean, standard deviation, 
and range); Aβ40, Aβ42, Aβ40/42 ratio, total tau (T-tau) and hyperphosphorylated tau (P-tau) 
(means and standard deviations in pg/mL); AVLT total recall score (mean and standard deviation); 
AVLT delayed recall score (mean and standard deviation); and Rr score (mean and standard 
deviation). The last column reports p values for t-tests or Fisher’s exact test (Females). 
 Cognitively Normal MCI-AD 
N (%) 110 (87%) 16 (13%) Significance 
Age at baseline 62.5 (9.2; 45-85) 72.7 (7.1; 60-83) p<0.001 
Females 79 (72%) 4 (25%) p<0.001 
Years of education 16.1 (2.5 ; 8-21) 16.2 (2.9 ; 12-20) p=0.847 
CSF Aβ40 10243.8 (3367.7)  8843.9 (2662.9) p=0.112a 
CSF Aβ42 1052.5 (393.5) 683.0 (218.1) p<0.001a 
40/42 ratio 10.3 (2.9) 14.2 (5.4) p<0.001a 
CSF T-tau 326.9 (178.4) 471.4 (263.6) p=0.007a 
CSF P-tau 43.6 (16.8) 51.9 (28.1) p=0.186a 
AVLT total recall 48.5 (8.8) 32.8 (5.5) p<0.001 
AVLT del. recall 2.2 (1.2) 0.6 (0.6) p<0.001 
Rr 1.2 (0.7) 2.3 (0.9) p<0.001a 
a: The analyses were carried out using natural log-transformed scores  
  




Table 2. Partial correlation coefficients, p-values, FDR-adjusted p-values, and bootstrapped 95% 
confidence intervals for analyses, divided by controls and MCI-AD. Significant correlations are 
reported in bold. If still significant after FDR-adjustment, also italicized. 
  Aβ40 Aβ42 Ratio T-Tau P-Tau 
Controls Total 
Recall 
Coefficient 0.033 -0.020 0.058 0.000 0.024 
p-value     0.735 0.841 0.551 1.000 0.803 
FDR-adj. p-value 1.000 1.000 1.000 1.000 1.000 
  95% 
Conf. 
Interval 
Lower -0.153 -0.211 -0.171 -0.179 -0.165 
Upper 0.218 0.186 0.276 0.167 0.195 
Delayed 
Recall 
Coefficient -0.040 -0.007 -0.032 -0.086 -0.096 
p-value     0.680 0.946 0.741 0.380 0.323 
FDR-adj. p-value 1.000 1.000 1.000 1.000 1.000 
  95% 
Conf. 
Interval 
Lower -0.226 -0.200 -0.243 -0.261 -0.267 
Upper 0.151 0.190 0.171 0.085 0.088 
Rr Coefficient 0.098 0.057 0.012 0.100 0.135 
p-value     0.313 0.557 0.902 0.305 0.164 
FDR-adj. p-value 1.000 1.000 1.000 1.000 1.000 
  95% 
Conf. 
Interval 
Lower -0.100 -0.131 -0.166 -0.090 -0.085 
Upper 0.286 0.246 0.187 0.276 0.334 
MCI-AD Total 
Recall 
Coefficient -0.021 0.279 -0.276 -0.232 -0.398 
p-value     0.946 0.357 0.361 0.445 0.178 
FDR-adj. p-value 0.946 0.548 0.548 0.556 0.445 
  95% 
Conf. 
Interval 
Lower -0.686 -0.486 -0.811 -0.778 -0.845 
Upper 0.66 0.8 0.35 0.446 0.265 
Delayed 
Recall 
Coefficient 0.082 0.467 -0.405 -0.309 -0.403 
p-value     0.789 0.107 0.170 0.305 0.172 
FDR-adj. p-value 0.845 0.445 0.445 0.548 0.445 
  95% 
Conf. 
Interval 
Lower -0.709 -0.32 -0.926 -0.873 -0.884 
Upper 0.757 0.863 0.347 0.417 0.271 
Rr Coefficient -0.208 -0.762 0.624 0.274 0.239 
p-value     0.495 0.002 0.023 0.365 0.431 
FDR-adj. p-value 0.571 0.030 0.173 0.548 0.557 
  95% 
Conf. 
Interval 
Lower -0.696 -0.952 -0.021 -0.386 -0.361 













a) Plot of CSF Aβ42 unstandardized residuals (age, education and sex; X-axis) by log-transformed Rr 
(Y-axis). Black represents individuals with MCI-AD, and grey represents healthy controls.  
b) Plot of CSF T-tau unstandardized residuals (age, education and sex; X-axis) by log-transformed Rr 
(Y-axis). Black represents individuals with MCI-AD, and grey represents healthy controls. 
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